Oncology

Latest News

In the phase 3 IMforte trial, patients with extensive-stage small cell lung cancer experienced clinically meaningful benefits with maintenance lurbinectedin plus atezolizumab vs atezolizumab. | Image credit: appledesign - stock.adobe.com
Lurbinectedin Plus Atezolizumab Maintenance Shows Improved Survival vs Atezolizumab in SCLC

May 22nd 2025

Patients with extensive-stage small cell lung cancer (SCLC) experienced clinically meaningful benefits with lurbinectedin plus atezolizumab vs atezolizumab in the phase 3 IMforte trial, according to findings being presented at the ASCO Annual Meeting.

AJMC Q&A with Eileen Peng, PharmD | Background image credit: ipopba - stock.adobe.com
The Role of Pharmacists Expands Beyond Dispensing for Novel Cancer Therapies: Eileen Peng, PharmD

May 21st 2025

Future validation studies with a larger sample size are warranted to ensure the technique will be useful in a clinical setting. | Image credit: Artur Wnorowski - stock.adobe.com
Novel, Noninvasive Skin Cancer Detection Method Shows Promise

May 18th 2025

FDA Approved | Image credit: chrisdorney – stock.adobe.com
Teliso-V Approved to Treat Advanced NSCLC With High c-Met Protein Overexpression

May 14th 2025

While CTCs were identified regardless of disease stage, the current study identified large variations in the presence of CTCs between nonmetastatic and metastatic disease | Image Credit: Innovative Creation - stock.adobe.com
Flow Cytometry Can Reliably Identify CTC in Melanoma

May 14th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Site Logo
December 13th 2016

Palliative Care for Patients With Advanced Illness: A Changing Policy Landscape

Sharon Pearce
A lag in policy changes has resulted in significant variation across palliative care programs for treating advanced illnesses. A recent shift in policy has, however, allowed small-scale testing of community-based palliative care delivery and some innovations in other delivery systems.
Site Logo
December 13th 2016

FDA Reaffirms Bladder Cancer Risk With Use of Pioglitazone

Surabhi Dangi-Garimella, PhD
The FDA has released an updated safety announcement following a fresh review of data on the type 2 diabetes treatment pioglitazon to confirm that the drug may increase a person’s likelihood of developing bladder cancer.
Site Logo
December 13th 2016

Step Therapy Cost-Effective for Psychological Distress in Patients With Cancer

AJMC Staff
A study published in the Journal of Clinical Oncology has found that step therapy can be cost-effective in patients with cancer who are under psychological duress.
Barry Russo on Quality Measures Data and Value Frameworks
December 13th 2016

Barry Russo on Quality Measures Data and Value Frameworks

Barry Russo, CEO of The Center for Cancer & Blood Disorders, said that his practice continues to collect quality and claims data from a number of sources, even though it isn’t easy. Russo also said that payers are not particularly interested in participating in a value framework, instead choosing to focus on the oncology care model (OCM).
Site Logo
December 12th 2016

Social Ties Significantly Impact Survival of Patients With Breast Cancer

Surabhi Dangi-Garimella, PhD
An exhaustive study conducted by researchers at the Kaiser Permanente Division of Research has found that a woman’s social network can significantly affect her chances of survival following breast cancer.
Site Logo
December 12th 2016

Achieving Value Through Palliative Care

Allison Silvers, MBA Stacie Sinclair, MPP Diane E. Meier, MD, FACP
Palliative care is an underutilized and powerful resource in the drive towards value. In the current article, we review published evidence and highlight how Medicare Advantage plans, accountable care organizations, and oncology practices can benefit from concurrent palliative care under value-based payments.
Site Logo
December 9th 2016

Smoking Cessation Programs Need a Boost Under Medicaid Expansion

Surabhi Dangi-Garimella, PhD
The CDC's Morbidity and Mortality Weekly Report recommends that Medicaid expansion states should direct more attention to smoking cessation programs to improve access and raise awareness about these programs among beneficiaries and providers.
Site Logo
December 9th 2016

Welcome to the Future: Telemedicine and Value-Based Payment

Michael D. Fratkin, MD Stephen G. Franey, MBA
By using telemedicine and relocating the center of care to where a person lives, we have an opportunity to address more unmet demand for palliative care, while giving more control to the seriously ill to meet their stated needs.
This Week in Managed Care: December 9, 2016
December 9th 2016

This Week in Managed Care: December 9, 2016

This week, the top stories in managed care included poll results that show growing numbers of Republicans want the Affordable Care Act scaled back instead of repealed, Jardiance received a new indication for patients with type 2 diabetes, and CareMore reported care coordination gaps for seniors.
Site Logo
December 8th 2016

Researchers Develop Model to Predict Chemotherapy Success in Aggressive Breast Cancer

Christina Mattina
At the 2016 San Antonio Breast Cancer Symposium, researchers announced the creation of a model to identify patients with triple negative breast cancer who are most likely to respond to chemotherapy.
Site Logo
December 8th 2016

Integrating Palliative Care Into Outpatient Oncology: A Case Study

Karen Mulvihill, DNP, APRN, FNP-BC, ACHPN
This article examines the integration of palliative care in a community cancer center-an example of how one program integrated palliative care.
Site Logo
December 7th 2016

ASCO Makes Recommendations to Reduce Cardiac Risk in Survivors of Adult-Onset Cancers

Surabhi Dangi-Garimella, PhD
A panel of 21 expert clinicians from the field conducted a systematic review of meta-analyses randomized clinical trials, observational studies, and clinical experience, to develop recommendations that have been published in the Journal of Clinical Oncology.
Site Logo
December 6th 2016

CAR T-Cells of Defined Composition Effective in Ibrutinib-Refractory CLL

Surabhi Dangi-Garimella, PhD
In high-risk patients with chronic lymphocytic leukemia (CLL), CD19 chimeric antigen receptor (CAR) T-cells of defined composition can be administered with an acceptable early toxicity.
Site Logo
December 5th 2016

Innovative Approach to Precision Trial Design: NCI-MATCH and Beat AML

Surabhi Dangi-Garimella, PhD
Representatives from the Beat acute myeloid leukemia (AML) and National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH), which incorporate genomic profiling to assign patients to different treatment arms, provided an insight on trial design and a progress report.
Dr Robert Carlson Discusses Future of Immuno-Oncology, Importance of Patient Advocacy
December 5th 2016

Dr Robert Carlson Discusses Future of Immuno-Oncology, Importance of Patient Advocacy

Immuno-oncology will be an important part of cancer care in the future, but probably not the only part, predicted Robert W. Carlson, MD, CEO of the National Comprehensive Cancer Network. He also explained how patient advocacy and an enduring healthcare system are essential to the advancement of cancer care.
Site Logo
December 5th 2016

RESONATE-2 Continues to Impress With Single-Agent Ibrutinib for CLL/SLL at 29 Months

Surabhi Dangi-Garimella, PhD
Older patients diagnosed with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) continue to present a favorable response to single-agent ibrutinib, at a follow-up of 29 months, in phase 3 of the RESONATE-2 trial.
Pam Mangat Explains How ASCO Works to Educate Oncologists on Precision Medicine
December 5th 2016

Pam Mangat Explains How ASCO Works to Educate Oncologists on Precision Medicine

Pam Mangat, MS, associate director TAPUR study at the American Society of Clinical Oncology, says that the organization has developed a number of initiatives to educate oncology practitioners on the potential of precision medicine, such as testing guidelines, online courses, a virtual tumor board, and clinical trials.
Site Logo
December 4th 2016

ASH Symposium on Quality Addresses Health IT Challenges for the Provider and the Patient

Surabhi Dangi-Garimella, PhD
The Special Symposium on Quality at the 58th American Society of Hematology Annual Meeting & Exposition, looked at how health information technology can be utilized to improve healthcare quality, enhance patient-provider shared decision-making, and facilitate efforts in quality research.
Site Logo
December 4th 2016

Phase 3 LyMa Trial: Rituximab After ASCT Improves OS in Mantle Cell Lymphoma

Surabhi Dangi-Garimella, PhD
Phase 3 results from the LyMa trial show that rituximab maintenance therapy after autologous stem cell transplant (ASCT) prolongs event-free survival, progression-free survival, and overall survival (OS) in previously untreated young patients with mantle cell lymphoma (MCL).
Dr Carrie Stricker Discusses IT Solutions That Engage Both Cancer Patients and Care Teams
December 4th 2016

Dr Carrie Stricker Discusses IT Solutions That Engage Both Cancer Patients and Care Teams

Innovative health IT tools like those developed by Carevive help maximize the balance between patient self-management and care team engagement, which is especially important in the era of value-based care, according to Carrie Stricker, PhD, RN, AOCN, chief clinical officer and co-founder of Carevive.
Dr Joseph Alvarnas on How Comorbidities Impact Care Decisions for Cancer Patients
December 4th 2016

Dr Joseph Alvarnas on How Comorbidities Impact Care Decisions for Cancer Patients

A cancer patient’s comorbid diseases have important implications for setting goals and selecting treatment, said Joseph Alvarnas, MD, of the City of Hope and editor-in-chief of Evidence-Based Oncology. Clinicians must keep comorbidities in mind as they base oncology care upon that person as an individual.
Site Logo
December 3rd 2016

Early Results Show Palbociclib Helps Sustain Patient Response to Ibrutinib in MCL

Surabhi Dangi-Garimella, PhD
Early phase 1 results show that including the cyclin-dependent kinase 4/6 inhibitor palbociclib in the treatment of patients with mantle cell lymphoma (MCL) can help overcome resistance to ibrutinib.
Site Logo
December 3rd 2016

Cytokine Biomarkers Can Predict Response to CAR T-Cell Treatment in CLL

Surabhi Dangi-Garimella, PhD
Distinct genetic signatures can help distinguish responders from nonresponders of chimeric antigen receptor (CAR) T-cell treatment in patients diagnosed with chronic lymphocytic leukemia (CLL).
David Fabrizio Says Surrogate Endpoints Will Help Accelerate Drug Discovery
December 3rd 2016

David Fabrizio Says Surrogate Endpoints Will Help Accelerate Drug Discovery

Surrogate endpoints, or endpoints other than overall survival, will help accelerate drug discovery and provide additional solutions for patients, according to David Fabrizio, of Foundation Medicine, Inc. However, alternate endpoints are not without their drawbacks.
Dr David Porter Compares Use of CAR T-Cells for B-Cell and Solid Tumors
December 3rd 2016

Dr David Porter Compares Use of CAR T-Cells for B-Cell and Solid Tumors

Chimeric antigen receptor (CAR) T-cells have been dramatically effective in treating B-cell cancers, according to David L. Porter, MD, of the University of Pennsylvania Health System. He also identified the use of CAR T-cells for treating solid tumors as a research area that will see more development in the coming years.
Site Logo
December 2nd 2016

NICE Recommends Pembrolizumab for Advanced Lung Cancer Following Additional Price Cut

AJMC Staff
NICE recommends pembrolizumab for use in advanced lung cancer following additional data review and a further discount in price.
Site Logo
December 2nd 2016

Genomic Changes Ensure Chemotherapy Response in Testicular Cancer

Surabhi Dangi-Garimella, PhD
Research from the Dana-Farber Cancer Institute and the Broad Institute, published in Nature, has identified genomic changes that could explain the development of testicular cancer and why this disease is more responsive to chemotherapy.
This Week in Managed Care: December 2, 2016
December 2nd 2016

This Week in Managed Care: December 2, 2016

This week, the top stories in managed care included the president-elect's picks for HHS and CMS, the American Diabetes Association addressed psychosocial care for patients with diabetes, and the American Society of Clinical Oncology released criteria on creating clinical pathways.
Site Logo
December 1st 2016

Precision CAR-T Trial Shows Early Signs of Success in Multiple Myeloma

Surabhi Dangi-Garimella, PhD
Interim data analysis of a phase 1 trial of chimeric antigen receptor-T cells (CAR-T) targeting the B-cell maturation antigen in heavily pretreated patients with multiple myeloma has identified an objective anti-tumor response, with limited toxicity.
Site Logo
November 30th 2016

Statins Could Reduce Mortality in Patients With Multiple Myeloma

Surabhi Dangi-Garimella, PhD
Statin use was associated with a reduction in all-cause and multiple myeloma-specific mortality.
<1
...
858687888990919293
...
185>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo